These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22249348)

  • 1. Posaconazole serum level on day 2 predicts steady state posaconazole serum level.
    Green MR; Woolery JE
    Ther Drug Monit; 2012 Feb; 34(1):118-9. PubMed ID: 22249348
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimising absorption of posaconazole.
    Green MR; Woolery JE
    Mycoses; 2011 Nov; 54(6):e775-9. PubMed ID: 21615538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
    Pea F; Furlanut M; Viale P
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3608-9; author reply 609-10. PubMed ID: 19617468
    [No Abstract]   [Full Text] [Related]  

  • 4. Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
    Prattes J; Duettmann W; Hoenigl M
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5595-9. PubMed ID: 27324763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
    Krishna G; Sansone-Parsons A; Kantesaria B
    Curr Med Res Opin; 2007 Jun; 23(6):1415-22. PubMed ID: 17559737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of timing for determination of posaconazole plasma concentrations.
    Heinz WJ; Zirkel J; Kuhn A; Schirmer D; Lenker U; Keller D; Klinker H
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3621-3. PubMed ID: 21502619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.
    Matthias KR; Nix DE; Peloquin CA; Graham ML
    Ann Pharmacother; 2012 Sep; 46(9):e22. PubMed ID: 22872751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
    Mohammedi I; Piens MA; Padoin C; Robert D
    Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
    [No Abstract]   [Full Text] [Related]  

  • 9. Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations.
    Hohmann C; Kang EM; Jancel T
    Clin Infect Dis; 2010 Mar; 50(6):939-40. PubMed ID: 20166829
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole plasma concentrations in critically ill patients.
    Ray J; Campbell L; Rudham S; Nguyen Q; Marriott D
    Ther Drug Monit; 2011 Aug; 33(4):387-92. PubMed ID: 21654350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole therapeutic drug monitoring: a reference laboratory experience.
    Thompson GR; Rinaldi MG; Pennick G; Dorsey SA; Patterson TF; Lewis JS
    Antimicrob Agents Chemother; 2009 May; 53(5):2223-4. PubMed ID: 19258264
    [No Abstract]   [Full Text] [Related]  

  • 13. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
    Bryant AM; Slain D; Cumpston A; Craig M
    Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.
    Müller C; Arndt M; Queckenberg C; Cornely OA; Theisohn M
    Mycoses; 2006; 49 Suppl 1():17-22. PubMed ID: 16961577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
    Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
    Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
    Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.
    van der Elst KC; Brouwers CH; van den Heuvel ER; van Wanrooy MJ; Uges DR; van der Werf TS; Kosterink JG; Span LF; Alffenaar JW
    Ther Drug Monit; 2015 Dec; 37(6):766-71. PubMed ID: 26565789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.
    Sansone-Parsons A; Krishna G; Calzetta A; Wexler D; Kantesaria B; Rosenberg MA; Saltzman MA
    Antimicrob Agents Chemother; 2006 May; 50(5):1881-3. PubMed ID: 16641468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
    Heinz WJ; Einsele H; Helle-Beyersdorf A; Zirkel J; Grau A; Schirmer D; Lenker U; Klinker H
    Transpl Infect Dis; 2013 Oct; 15(5):449-56. PubMed ID: 23890126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral fluconazole in autologous bone marrow transplantation recipients given TBI and high-dose melphalan.
    Milliken S; Powles R; Jones A; Helenglass G
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3067. PubMed ID: 2539685
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.